OTCMMYCOF
Market cap105kUSD
Dec 20, Last price
0.00USD
1D
-31.03%
1Q
-46.67%
IPO
-99.60%
Name
Mydecine Innovations Group Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
208.75%
Rev. gr., 5y
%
Revenues
0k
Net income
-21m
L+76.79%
CFO
-4m
L-49.96%
Earnings
Aug 14, 2025
Profile
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 7 -87.19% | |||||||||
Cost of revenue | 9,392 | 13,701 | 18,705 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (9,392) | (13,701) | (18,698) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (5,393) | 5,137 | ||||||||
Tax Rate | ||||||||||
NOPAT | (9,392) | (8,308) | (23,834) | |||||||
Net income | (20,947) 76.79% | (11,849) -58.74% | (28,720) 4.22% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 3,608 | 6,908 | 15,333 | |||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 5,423 | 85 | 80 | |||||||
Long-term debt | 4,697 | 4,570 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 5,386 | 153 | 3,154 | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (4,217) | (8,428) | (24,052) | |||||||
CAPEX | (35) | (404) | ||||||||
Cash from investing activities | 525 | (38) | (474) | |||||||
Cash from financing activities | 3,718 | 6,981 | 23,831 | |||||||
FCF | (2,891) | (6,894) | (25,022) | |||||||
| Balance | ||||||||||
Cash | 38 | 4,629 | 1,495 | |||||||
Long term investments | ||||||||||
Excess cash | 38 | 4,629 | 1,495 | |||||||
Stockholders' equity | (28,989) | (20,388) | (17,077) | |||||||
Invested Capital | 22,497 | 21,570 | 21,790 | |||||||
ROIC | ||||||||||
ROCE | 144.68% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 30,697 | 8,647 | 4,682 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (9,383) | (13,572) | (18,462) | |||||||
EV/EBITDA | ||||||||||
Interest | 1,303 | 912 | 205 | |||||||
Interest/NOPBT | ||||||||||